>
产品中心 >
Functional_antibody >
Adipogen/anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (preservative free)/AG-27B-6000PF-C100/100 µg
| ProductDetails | |
|---|---|
| Synonyms | TNF-α-convertingEnzyme;DisintegrinandMetalloproteinaseDomain-containingProtein17;CD156b |
| ProductType | MonoclonalAntibody |
| Properties | |
| Clone | D1(A12) |
| Isotype | HumanIgG1 |
| Source/Host | E.coli |
| Immunogen/Antigen | RecombinanthumanADAM17(TACE)ectodomaintaggedtobiotin. |
| Label/Conjugates | PreservativeFree |
| Application | FunctionalApplication(Blocking):InhibitsADAM17activityat30μg/ml(200nM). |
| Crossreactivity | Human |
| Specificity | Recognizesthecatalyticandnon-catalyticdomainofhumanADAM17(TACE)throughitsvariablelight(VL)domainandvariableheavy(VH)domain,respectively.DoesnotbindrecombinantmouseADAM17ectodomain. |
| Purity | ≥95%(SDS-PAGE) |
| PurityDetail | ProteinA/G-affinitypurified. |
| EndotoxinContent | <0.001eu mu;g=""> |
| Concentration | 1mg/ml |
| Formulation | Liquid.InPBS. |
| OtherProductData | Thiscross-domainhumanantibodyisaselectiveADAM17(TACE)antagoNISTandprovidesauniquealternativetosmallmoleculemetalloproteaseinhibition.ADAMmultidomaintopologywasexploitedbyfirstisolatinganinhibitoryhumanantibody(D1)thatboundADAM17-specificnon-catalyticregionsexclusivelythroughitsvariableheavy(VH)domain.AD1-VHbiasedscFvphage-displaylibrarywasthenusedtoselectivelyisolateanewvariablelight(VL)chainthatcouldsimultaneouslybindtotheADAM17catalyticdomain. |
| AccessionNumber | UniProtIDP78536 |
| ShippingandHandling | |
| Shipping | BLUEICE |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Avoidfreeze/thawcycles. |
| Use/StABIlity | Stableforatleast1yearafterreceiptwhenstoredat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
ADAM17(Disintegrinandmetalloproteinasedomain-containingprotein17),alsocalledTACE(Tumornecrosisfactor-α-convertingenzyme)istheprototypeoftheADAMfamilyofectodomainsheddingproteases(sheddase).ADAM17isunderstoodtobeinvolvedintheprocessingofTNF-αatthesurfaceofthecellandfromwithintheintracellularmembranesofthetrans-Golginetwork.Thisprocessinvolvesthecleavageandreleaseofasolubleectodomainfrommembrane-boundpro-proteins(suchaspro-TNF-α)andisofknownphysiologicalimportance.ADAM17isresponsIBLefortheprocessingofadiversevarietyofmembrane-anchoredcytokines,celladhesionmolecules,receptors,ligandsandenzymes,includingcleavingepidermalgrowthfactorreceptor(EGFR)ligandsandextracellularNotch1.Theproteolyticcleavageisanindispensableactivationeventformanyofthesesubstrates,ADAM17hasemergedasanattractivetherapeutictargetforthetreatmentofinflammatorydiseases(e.g.rheumatoidarthritis)orinflammationassociatedcancer.
- Cross-domaininhibitionofTACEectodomain:C.J.Tape,etal.;PNAS108,5578(2011)
- Anti-tumoureffectsofaspecificanti-ADAM17antibodyinanovariancancermodelinvivo:F.M.Richards,etal.;PLoSOnee40597(2012)
- iRHOM2isacriticalpathogenicmediatorofinflammatoryarthritis:P.D.Issuree,etal.;J.Clin.Invest.123,928(2013)
- NKcellCD16surfaceexpressionandfunctionisregulatedbyadisintegrinandmetalloprotease-17(ADAM17):R.Romee,etal.;Blood121,3599(2013)
- Developmentofa"mouseandhumancross-reactive"affinity-maturedexositeinhibitoryhumanantibodyspecifictoTACE(ADAM17)forcancerimmunotherapy:H.F.Kwok,etal.;ProteinEng.Des.Sel.27,179(2014)
- TargetingthesheddaseactivityofADAM17byananti-ADAM17antibodyD1(A12)inhibitsheadandnecksquamouscellcarcinomacellproliferationandmotilityviablockageofbradykinininducedHERstransactivation:Y.Huang,etal.;Int.J.Biol.Sci.10,702(2014)
- TargetingADAM-17withaninhibitorymonoclonalantibodyhasantitumoureffectsintriple-negativebreastcancercells:F.Caiazza,etal.;Br.J.Cancer112,1895(2015)
- Recentadvancesinthefieldofanti-cancerimmunotherapy:H.Neves&H.F.Kwok;BBAClinical3,280(2015)(Review)
